Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Donation - Other Level

Please use the quantity box to donate any amount you wish. Sign Up to Donate


Send a question or comment using the form below. This message may be routed through support staff.

Email Article

Password Reset Request


Add a topic or expert to your feed.


Follow Experts & Topics

Stay on top of our work by selecting topics and experts of interest.

On The Ground
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed

Manhattan Institute

Close Nav
Share this commentary on Close

Available Drugs, Affordable Drugs


Available Drugs, Affordable Drugs

National Review March 21, 2017
Health PolicyFDA ReformDrug Development

A prescription for the new FDA commissioner

Over the past several months, President Trump has given the biotech industry a preview of the grand bargain he expects from it: It will accept more U.S.-based manufacturing and lower drug prices for government programs, in return for tax reform that would benefit the industry, tougher trade deals that would better protect U.S. biotech patents (in Canada, China, and elsewhere), improved market access in the U.K. and in Germany and other EU countries, and, most important, streamlined Food and Drug Administration regulations.

His broadsides against the industry, both during the 2016 campaign and after his November 8 victory, have left executives and investors nervous, and with good reason. His rhetoric on drug pricing is indistinguishable from that of Senator Bernie Sanders. In early January, in his first press conference as president-elect, Trump said that the industry was “getting away with murder” on drug pricing, adding that “pharma has a lot of lobbies, a lot of lobbyists, and a lot of power,” with “very little bidding on drugs.” He said that America, meaning the federal government, is through Medicare, Medicaid, and other entitlement programs the “largest buyer of drugs in the world, and yet we don’t bid properly.”

Read the entire piece here in the April 3, 2017, Issue of National Review (paywall)


Paul Howard is a senior fellow and director of health policy at the Manhattan Institute. Follow him on Twitter here.

Photo by Pool / Getty